Comparison of influence of allopurinol and febuxostat on IL-1β and NALP3 levels and liver and kidney function in gout patients with hyperuricemia
10.3760/cma.j.issn.1008-6706.2018.11.024
- VernacularTitle: 非布司他与别嘌醇对痛风伴高尿酸血症患者白细胞介素1β和核苷酸结合寡聚化结构域样受体3水平及肝肾功能的影响比较
- Author:
Huiyun HUANG
1
;
Yueping XU
Author Information
1. Department of Pharmacy, the People's Hospital of Cixi, Cixi, Zhejiang, 315300, China
- Publication Type:Journal Article
- Keywords:
Gout;
Hyperuricemia;
Febuxostat;
Allopurinol
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(11):1452-1455
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To study the influence of allopurinol and febuxostat on IL-1β and NALP3 levels and liver and kidney function in gout patients with hyperuricemia.
Methods:A total of 108 patients with stable gout accompanied by hyperuricemia were selected and randomly divided into control group and observation group according to the digital table, with 54 cases in each group.The control group was given allopurinol 100mg/time, orally, 3 times/d.The observation group was given febuxostat 40mg/time, orally, 1 time/d.The two groups were treated 4 weeks for 1 course, continuous treatment for 6 courses.The contents of serum IL-1β and NALP3, and renal function[creatinine(Scr), urea nitrogen(BUN), glomerular filtration rate(GFR) and uric acid(UA)], liver function[alanine aminotransferase(ALT) and aspartate aminotransferase(AST)]of the two groups were detected, and the adverse reaction of the two groups were observed.
Results:After treatment, the contents of serum IL-1β and NALP3 of the observation group decreased gradually, which were lower than those of the control group(t=1.910, 2.196, 4.954, 1.732, 5.944, 7.935, all P<0.05). After treatment, the blood UA of the two groups decreased significantly, the blood UA of the observation group was lower than the control group(t=9.772, P<0.05). The other kidney function indicators had no statistically significant differences between the two groups (t=0.082, 0.923, 1.395, all P>0.05). The liver function indicators of the two groups had no statistically significant differences(t=0.860, 0.563, all P>0.05). The incidence rate of adverse reactions in the observation group was 5.77%, which was lower than 20.75% in the control group(χ2=5.101, P=0.024).
Conclusion:Febuxostat in the treatment of gout with hyperuricemia can effectively reduce the level of serum UA, and inhibit the expression of inflammatory factors such as IL-1β and NALP3, with high safety, which is worthy of clinical promotion.
